GlassScriptPhysician profile
April Halleron
NPI 1720306582
$2,989.85
in general payments reported to CMS, 2019-2025
31 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $292 · 2021: $219 · 2022: $98.13 · 2023: $734 · 2024: $709 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,640.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $432.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $380.53 | 2019-2024 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $257.01 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $225.05 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $224.41 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $199.34 | 2019-2023 | |
| Abbvie INC. | $181.17 | 2019-2024 | |
| Pfizer INC. | $154.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.56 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $123.81 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.80 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $82.02 | 2019-2022 | |
| Astellas Pharma US INC | $63.92 | 2019-2025 | Veozah |
| Dynavax Technologies Corporation | $57.04 | 2024-2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $44.66 | 2023 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $30.64 | 2019-2020 | |
| Abbott Laboratories | $30.38 | 2023-2024 | Freestyle Libre 3, Freestyle Libre |
| Merck Sharp & Dohme LLC | $27.75 | 2019-2025 | Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $26.97 | 2019-2020 | |
| Allergan, INC. | $26.83 | 2019-2020 | |
| Exact Sciences Corporation | $26.69 | 2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $25.52 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.28 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.17 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $17.65 | 2025 | Rexulti |
| Circassia INC. | $16.82 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.75 | 2024 | Caplyta |
| Boston Scientific Corporation | $15.72 | 2022 | |
| Dexcom, INC. | $14.22 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $13.54 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Halleron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.